The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase‐plasminogen activator and matrix metalloproteinase‐2
Abstract
Cancer metastasis, involving multiple processes and various cytophysiological changes, is a primary cause of cancer death and may complicate the clinical management, even lead to death. Silibinin is a flavonoid antioxidant and wildly used for its antihepatotoxic properties and recent studies have revealed pleiotropic anticancer and antiproliferative capabilities of silibinin. In this study, we first observed that silibinin exerted a dose‐ and time‐dependent inhibitory effect on the invasion and motility, but hardly on the adhesion, of highly metastatic A549 cells in the absence of cytotoxicity. To look at the precise involvement of silibinin in cancer metastasis, A549 cells were treated with silibinin at various concentrations, up to 100 μM, for a defined period and then subjected to gelatin zymography, casein zymography and Western blot to investigate the impacts of silibinin on metalloproteinase‐2 (MMP‐2), urokinase plasminogen activator (u‐PA), and tissue inhibitor of metalloproteinase‐2 (TIMP‐2), respectively. The results showed that a silibinin treatment may decrease the expressions of MMP‐2 and u‐PA in a concentration‐ and time‐dependent manner and enhance the expression of TIMP‐2. Further analysis with semi‐quantitative RT‐PCR showed that silibinin may regulate the expressions of MMP‐2 and u‐PA on the transcriptional level while on the translational or post‐translational level for TIMP‐2. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575
Giancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Olaso, E., Labrador, J.-P., Wang, L., Ikeda, K., Eng, F. J., Klein, R., Lovett, D. H., Lin, H. C., & Friedman, S. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107571200 · Cited by 238 · cited 1×
“2% Triton X-100 and the absorbance was measured at 550 nm [21].”
BackgroundMatrix metalloproteinases and cellular fibrinolytic activity
Lijnen, H. R. (2002) · Biochemistry (Moscow) · doi:10.1023/a:1013908332232 · Cited by 167
Cited by
Silybin and silymarin - new effects and applications
Křen, V., & Walterová, D. (2005) · Biomedical Papers · doi:10.5507/bp.2005.002 · Cited by 446
Multitargeted therapy of cancer by silymarin
Ramasamy, K., & Agarwal, R. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.053 · Cited by 442
Chen, P.-N., Chu, S.-C., Chiou, H.-L., Kuo, W.-H., Chiang, C.-L., & Hsieh, Y.-S. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.04.033 · Cited by 423
Self-citationAntimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer
Deep, G., & Agarwal, R. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9237-0 · Cited by 253
Lee, H., Kim, J.-S., & Kim, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050624 · Cited by 191
Metadata
- Authors
- Chu, S., Chiou, H., Chen, P., Yang, S., & Hsieh, Y.
- Venue
- Molecular Carcinogenesis
- Publisher
- Wiley
- Published
- 2004-05-26
- Volume
- 40
- Issue
- 3
- Pages
- 143-149
- ISSN
- 0899-1987 (ISSN-L)
- 1098-2744
- OpenAlex
- W2135493260
- Cited by
- 176
- References
- 4
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.